Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NECTAR trial in relapsed pediatric T-cell ALL/lymphoblastic lymphoma
NL-OMON39457Phase 2Active, not recruiting
- Sponsor
- Children's Hospital Los Angeles
- Start
- Jul 2013
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nelarabine, etoposide and cyclophosphamide in t-cell acute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LBL), sponsored by Children's Hospital Los Angeles. Primary endpoint: Recommended phase II dose of nelarabine in combination with cyclophosphamide and etoposide. Started Jul 2013; status: active, not recruiting.
02
Drugs
nelarabineetoposidecyclophosphamide
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T-lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NL-OMON39457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39457.